

FY15 Earnings

Chennai, India – May 28, 2015

Orchid Pharma registers turnover of Rs 1753 crore in FY15

Financial highlights for year ended March 31, 2015 (FY15) - Standalone

Revenue of Rs 1753 crore [US\$ 280.6 million] registered during the year ended March 31, 2015 (FY 13-15 /18 months) as compared to Rs 1946 crore [US\$ 311.4 million] registered during the corresponding year ended March 31, 2013 [18 months].

Earnings before Interest, Depreciation and Tax (EBIDTA) stood at Rs 361 crore [US\$ 57.8 million] for the fiscal under review compared to Rs 169.60 crore [US\$ 27.1 million] registered during FY13

Net (Loss) for the fiscal ended March 31, 2015 stood at Rs (191) crore [US\$ (30.6) million] compared to a loss of Rs (530) crore [US\$ (84.8) million] for the previous fiscal

EPS for the fiscal ended March 31, 2015 stood at Rs. (26.11)

*** 1 US\$ = Rs 62.50**

The company extended its current financial and accounting year by six months to *March 31, 2015. This is to fall in line with the new Companies Act requirement.*

Update on the Corporate Debt Restructuring (CDR) initiative and the Business Transfer Agreement (BTA) with Hospira

The Company was admitted by Corporate Debt Restructuring (CDR) cell for restructuring its loans and the CDR package was finalized in December 2013 and approved by the CDR EG in March 2014. The Business Transfer Agreement (BTA) entered into with Hospira a part of the CDR initiative was implemented in July 2014 in line with the CDR process.


Shri R Kannan has been appointed as an independent, non-executive director and Ms Soundara Kumar has been appointed as a nominee of the Lenders as per the CDR package. She would be a non-executive director on the Board of Orchid. Shri S Yuvaraj an independent member on the Board vacates the Office of Director.

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA

Orchid Pharma FY15 earnings

**For ORCHID CHEMICALS &
PHARMACEUTICALS LTD.**

28/05/15


Executive Vice President - Finance & Secretary

From the Managing Director

"The approval of the CDR package and its implementation during the year with the support of the Lenders and Financial Institutions has helped us put operations of the remaining business back on track. The allocation of part of the sales proceeds for working capital requirements, reduced interest rates on the loans with a moratorium of 2 years for repayment of the principal and interest has improved the level of operations. Given our quality standards and new product pipeline, we are confident of better performance going forward," said Mr K Raghavendra Rao, Managing Director, Orchid Chemicals & Pharmaceuticals Ltd.

About Orchid Pharma

Orchid Chemicals & Pharmaceuticals Ltd. is a leading pharmaceutical company headquartered in Chennai, India involved in the development; manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. With exports spanning more than 75 countries, Orchid is the largest manufacturer-exporter of cephalosporin bulk actives in India and is ranked amongst the Top 5-cephalosporin producers in the world. Orchid's world-class manufacturing infrastructure including USFDA and UK MHRA approved API and dosage form facilities are located at Chennai. Orchid has dedicated state-of-the-art GLP compliant R&D centres for API research, drug discovery and pharmaceutical research at Chennai. Orchid has ISO 14001 and OHSAS 18001 certifications. Orchid is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in India.

Additional information is available at the company's website at www.orchidpharma.com

Safe Harbour

This release may include forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects" and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in the markets we operate in;
- The ability to successfully implement our strategies, our research and development efforts, growth and expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry


Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events.

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA

Orchid Pharma FY15 earnings

**For ORCHID CHEMICALS &
PHARMACEUTICALS LTD.**

28/05/15



Executive Vice President - Finance & Secretary